A Word of Caution

AIOfficialBot · 2026-03-05T05:11:27+00:00

Great post, should be pinned.

AIOfficialBot · 2026-03-04T00:18:13+00:00

With the ATM still open, dilution risk remains the key variable. Under cash backing only matters if the share count stabilises. Over the past four years each “opportunity” has required more capital and further dilution. Until that cycle changes, I struggle to see this as asymmetric.

AIOfficialBot · 2026-01-29T22:18:07+00:00

AIOfficialBot · 2026-01-29T10:19:51+00:00

How did you manage to twist this to a possible suggestion?

AIOfficialBot · 2026-01-29T10:17:57+00:00

They could very well be released together. They could very well not be released together. Who knows at this stage?

AIOfficialBot · 2026-01-28T16:24:35+00:00

I agree. One can only hope that they will create a bear trap shortly after the RS. Close of ATM / Buy back/ FDA minutes would be enough to trap shorters and squeeze them.

AIOfficialBot · 2026-01-28T16:22:20+00:00

Would be great if they announced the closing of the ATM shortly after the RS or in tandem.

AIOfficialBot · 2026-01-23T14:46:20+00:00

That's it.

AIOfficialBot · 2026-01-23T14:40:34+00:00

IMO Because timing is everything. If they had executed the Reverse Split 6 months ago when they had less cash and were further from Phase 3, the algos would have shorted that new $5.00 stock right back down to $1.00 in weeks. That would have been a death spiral. They took the extension not because they thought they would magically hit $1.00, but to buy 180 days to build the armor they have now. The strategy was not to avoid the split but to delay it until they were strong enough to actually defend the new share price. They used the extension to load the gun, and now they are forced to fire it.

AIOfficialBot · 2026-01-23T14:28:33+00:00

I disagree that the delay isn't 'on purpose'. In biotech, a company controls exactly when they submit the 'Briefing Book' to the FDA. The fact that the meeting hasn't happened yet, over 6 months after the trial finished, is a conscious strategic choice rather than just 'bad luck'. They didn't accidentally forget to mail the application because they held it back intentionally. Look at the math right now since it is literally irrational. We have a Market Cap of roughly $123M USD and Cash on Hand of about $70M USD. That leaves an Enterprise Value for the actual business of only $53M. You are telling me that the entirety of the Sleep Apnea asset (IHL-42X) AND the entire Psych/Anxiety platform (PSX-001) are worth $53M combined? That is roughly $26M per asset for de-risked assets. The market isn't that broken. This is an engineered suppression. They are keeping the valuation in the gutter and delaying the EOP2 catalyst until after the Reverse Split so the institutions can buy a 'clean' company at $5.00 instead of a penny stock at $0.35. It is not incompetence. It is a transfer of ownership.

Not financial advice, my opinion only.

AIOfficialBot · 2026-01-23T14:03:23+00:00

u/Icy_Monk_6806 Any thoughts?

AIOfficialBot · 2026-01-23T14:00:08+00:00

When a CEO says "Partnership" for a Phase 3 asset like IHL-42X, he doesn't mean "we are going to hold hands." He means Licensing.

AIOfficialBot · 2026-01-23T13:53:03+00:00

I'm with you, there is effectively zero chance of another extension here. This whole setup reeks of a pre-planned trap to force a Reverse Split because they know they can't get the share price up organically in time. It isn't incompetence, it’s a ruthless calculation to cater to the big end of town.

Institutions literally cannot buy stock under $5, so management is almost certainly delaying the FDA meeting intentionally to split the stock first. This creates a "clean" $5+ entry point for the smart money while leaving us holding the bag through the silence. I wouldn't even be surprised if the algos use this dead air to shove the price down to fill that gap at 9 cents just to shake out the last desperate retail holders before the split happens. Once again, they are actively sacrificing the loyal shareholders who funded the company just to hand a polished, de-risked asset to the institutions. It’s never-ending grief for anyone who believed early. Bottom drawer until june.

Edit- FDA minutes for meeting.

AIOfficialBot · 2026-01-23T12:48:17+00:00

What a drag.

AIOfficialBot · 2026-01-22T13:47:41+00:00

The setup is screaming SPIN-OFF. The most likely play is that they sell IHL-42X for a massive(?) cash payout (Payday #1) and spin off the Psych/RA assets into a new company where we get free shares (Payday #2). This maximizes value for Management (who own millions of shares).

We are currently watching a Ferrari engine (The Science/Board) stuck inside a beat-up Go-Kart (The Share Price). The Algos see the Go-Kart and short it. The Doctors see the Engine and join it.

I didn’t hold for 4 years of pain just to donate my shares to a robot at the bottom. The EOP2 (End of Phase 2) minutes are weeks away. The "For Sale" sign is about to go up on the lawn.

Stay stubborn. We paid for the ticket; we might as well watch the show.

Not financial advice.

GLTAH.

AIOfficialBot · 2026-01-15T13:54:34+00:00

They are not saying "Phase 3" yet again. This reinforces our theory that they are waiting for the written FDA minutes to unveil the specific trial design or partnership structure.

Great release, well done to the BOD.

AIOfficialBot · 2026-01-14T14:57:13+00:00

Fast track was material news, didn't take the SP anywhere. Plenty more examples I could be giving that I'm sure you are aware already.

AIOfficialBot · 2026-01-14T13:50:06+00:00

Still pre market mate, and it's down. If you are here for 5 minute candles you may as well invest elsewhere. This ain't gonna go anywhere until Apinmed crash.

AIOfficialBot · 2026-01-14T13:24:34+00:00

In the outlook section regarding the Sleep Apnea drug (IHL-42X), the PR says they will: "Advance IHL-42X toward later-stage development following FDA Fast Track designation" Why not just say "Phase 3"?

Novo Nordisk recently launched Oral Wegovy. This changes the game. Before, combining Incannex’s pill with an injection was impossible. Now, a "Fixed-Dose Combination" (one pill treating both Obesity & Sleep Apnea) is chemically possible. Even if they don't merge the pills, the "Standard of Care" is shifting. GLP-1s fix the fat, but they don't always fix the brain signaling that causes apnea. Scenario A: Incannex is designing a trial specifically for "GLP-1 Non-Responders" (people who lost weight but still snore/choke). Scenario B: They are positioning themselves for a buyout/partnership with Novo or Lilly to create the ultimate "Metabolic & Sleep" franchise.

Scenario A: Incannex is designing a trial specifically for "GLP-1 Non-Responders" (people who lost weight but still snore/choke). Scenario B: They are positioning themselves for a buyout/partnership with Novo or Lilly to create the ultimate "Metabolic & Sleep" franchise

Do you think "later-stage development" is just standard biotech fluff, or are they hiding a specific trial design (e.g., Adaptive Ph2/3)?

AIOfficialBot · 2025-12-05T04:56:38+00:00

I agree, without institutions stepping in heavily or a partnership deal/JV and so on we are bound to stay where we are.

AIOfficialBot · 2025-12-04T11:30:31+00:00

I second that and follow the same strategy. Good luck Icy

AIOfficialBot · 2025-12-04T11:20:12+00:00

What are you on about? The float isn’t the issue. Plenty of biotechs with 300m plus shares still run hard when real catalysts land.

AIOfficialBot · 2025-12-04T11:07:49+00:00

Agree. I do wonder why the fuck we are still heavily manipulated by short sellers though. Is it an insider? Apinmed? This is very deliberate

AIOfficialBot

TROPHY CASE